Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Deferred Tax (2017 - 2026)

Corcept Therapeutics (CORT) has disclosed Long-Term Deferred Tax for 10 consecutive years, with $181.6 million as the latest value for Q1 2026.

  • For Q1 2026, Long-Term Deferred Tax rose 25.7% year-over-year to $181.6 million; the TTM value through Mar 2026 reached $181.6 million, up 25.7%, while the annual FY2025 figure was $168.2 million, 28.48% up from the prior year.
  • Long-Term Deferred Tax hit $181.6 million in Q1 2026 for Corcept Therapeutics, up from $168.2 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $181.6 million in Q1 2026 and bottomed at $37.7 million in Q1 2022.
  • Average Long-Term Deferred Tax over 5 years is $106.2 million, with a median of $97.9 million recorded in 2024.
  • On a YoY basis, Long-Term Deferred Tax climbed as much as 123.88% in 2022 and fell as far as 1.86% in 2022.
  • Corcept Therapeutics' Long-Term Deferred Tax stood at $61.5 million in 2022, then soared by 47.41% to $90.6 million in 2023, then skyrocketed by 44.49% to $130.9 million in 2024, then rose by 28.48% to $168.2 million in 2025, then rose by 7.95% to $181.6 million in 2026.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $181.6 million, $168.2 million, and $153.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.